Clinical Trial Update: A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic/pharmacodynamic study of vibegron (MK-4618) in women with overactive bladder was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Vibegron (vibegron)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Overactive Bladder, Overactive Urinary Bladder | Phase 1 | Status: TERMINATED | Results posted: 2016-09-26